2005 — This publication covers mechanisms and consequences of mechanical and electrical remodeling in heart failure (HF), controlled trials of cardiac resynchronization therapy (CRT) alone or combined with implantable cardioverter defibrillator, and expanded indications for electrical heart failure devices.
This document has been retired because it is no longer current.
May 5, 2011 — Developed as a joint project with the American Society of Anesthesiologists (ASA), and in collaboration with the American Heart Association (AHA) and the Society of Thoracic Surgeons (STS), a diverse panel of experts in pacemaker and defibrillator management focused on medical procedures that might interfere with Cardiovascular Implantable Electronic Devices (CIEDs) function.
March 28, 2014 - A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society; developed in collaboration with the Society of Thoracic Surgeons. The goal of this guideline is to establish revised guidelines for optimum management of atrial fibrillation. This guideline supersedes the "2006 ACC/AHA/ESC Guideline for the Management of Patients with Atrial Fibrillation" and the two subsequent focused updates from 2011.
August 2011 (Update) — A fellowship curriculum is indispensable in the training of a clinical cardiac electrophysiologist. A CCEP curriculum was first published in 2001 and served as the basis for education in many fellowship programs. Over the last decade, cardiac electrophysiology continued to grow, evolve, and mature, which necessitated an update.
December 2001 — This position paper outlines the basic science, clinical components, and procedural aspects of electrophysiology and provides relevant references that can be used as an educational guide.
June 6, 2007 — Amiodarone is commonly used to treat supraventricular and ventricular arrhythmias in various inpatient and outpatient settings. Because of adverse drug reactions, proper use is essential to deriving optimal benefits from the drug with the least risk.
May 9, 2014 - This international expert consensus statement was written by experts in the field who were chosen by the Heart Rhythm Society in collaboration with representatives from the American College of Cardiology, American College of Chest Physicians, American Heart Association, Asia Pacific Heart Rhythm Society, European Hear Rhythm Association, and World Association for Sarcoidosis and Other Granulomatous Disorders (WASOG).
May 9, 2014 - This expert consensus statement was written by experts and developed in partnership with and endorsed by the American College of Cardiology Foundation (ACCF) and the American Heart Association (AHA); and in collaboration with and endorsed by the Heart Failure Society of America (HFSA) and the Society of Thoracic Surgeons (STS). Endorsed by the European Heart Rhythm Association (EHRA), the Asia Pacific Heart Rhythm Society (APHRS) and the Sociedad Latinoamericana de Estimulacion Cardiaca y Electrofisiologia (SOLAECE)-Latin American Society of Cardiac Pacing and Electrophysiology.
August 30, 2014-This international consensus statement of the European Heart Rhythm Association (EHRA), Heart Rhythm Society (HRS), and Asia Pacific Heart Rhythm Society is intended to provide clinical guidance for the management of patients with ventricular arrhythmias (VAs). It summarizes the consensus of the international writing group members and is based on a systematic review of the medical literature regarding Ventricular Arrhythmias.
May 8, 2014 - This expert consensus statement was developed in partnership between the Pediatric and Congenital Electrophysiology Society (PACES) and the Heart Rhythm Society (HRS) and endorsed by the governing bodies of PACES, HRS, the American College of Cardiology (ACC), the American Heart Association (AHA), the European Heart Rhythm Association (EHRA), the Canadian Heart Rhythm Society (CHRS), and the International Society for Adult Congenital Heart Disease (ISACHD).